Radioiodine dose for remnant ablation in differentiated thyroid carcinoma: A randomized clinical trial in 509 patients

被引:108
|
作者
Bal, CS [1 ]
Kumar, A [1 ]
Pant, GS [1 ]
机构
[1] All India Inst Med Sci, Dept Nucl Med, New Delhi 110029, India
来源
关键词
D O I
10.1210/jc.2003-031152
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Remnant ablation can be achieved by either administering an empiric fixed dose or using dosimetry-guided techniques. Because of the technical and logistic difficulties, most centers have adapted the fixed-dose or standard-dose technique for remnant ablation using (131)I. In the late 1970s, low- dose (131)I remnant ablation was introduced, and subsequently many centers confirmed the effectiveness of such therapy. However, the optimal dose (administered activity) of (131)I for remnant ablation is not yet settled. In a randomized clinical trial to find out the smallest possible effective dose for remnant ablation in cases of differentiated thyroid carcinoma, between July 1995 and January 2002, 565 patients were randomized into eight groups according to (131)I administered activity, starting at 15 mCi and increasing activity in increments of 5 mCi until 50 mCi. In the postrandomization phase, 56 patients were excluded from the study for various reasons, and final analysis was done with 509 patients. The mean age of the patients was 37.5+/-12.7 yr with a female to male ratio of 2.6. The surgical procedure was total/near-total thyroidectomy in 72% and subtotal or hemithyroidectomy in the rest. Histology was papillary thyroid carcinoma in 80.6% of patients and follicular thyroid carcinoma in the rest. With one dose of (131)I, remnant ablation was achieved in 59.6, 63.6, 81.4, 83.6, 79.4, 78.3, 84.4, and 81.8% of patients in the 15- to 50-mCi groups, respectively (overall ablation rate, 77.6%). The successful ablation rate was statistically different in patients receiving less than 25 mCi of (131)I compared with those receiving at least 25 mCi [63 of 102 (61.8%) vs. 332 of 407 (81.6%); P=0.006]. However, there was no significant intergroup difference in outcome among patients receiving 25-50 mCi of (131)I. Patients with small tumor size (less than or equal to5 cm), adequate surgery (total/near-total thyroidectomy), and radioiodine neck uptake of less than or equal to 10% had odds ratios of 2.4 [confidence interval (CI), 1.3-3.98], 2.6 (CI, 1.6-4.2), and 2.2 (CI, 1.4-3.5), respectively, for successful remnant ablation. Patients receiving at least 25 mCi of (131)I had a three times better chance of getting remnant ablation than patients receiving lesser activity of (131)I. Any activity of (131)I between 25 and 50 mCi appears to be adequate for remnant ablation.
引用
收藏
页码:1666 / 1673
页数:8
相关论文
共 50 条
  • [31] Could short thyroid hormone withdrawal be an effective strategy for radioiodine remnant ablation in differentiated thyroid cancer patients?
    Piccardo, Arnoldo
    Puntoni, Matteo
    Ferrarazzo, Giulia
    Foppiani, Luca
    Bottoni, Gianluca
    Altrinetti, Vania
    Treglia, Giorgio
    Naseri, Mehrdad
    Dib, Bassam
    Cabria, Manlio
    Trimboli, Pierpaolo
    Massollo, Michela
    Giovanella, Luca
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 (07) : 1218 - 1223
  • [32] Could short thyroid hormone withdrawal be an effective strategy for radioiodine remnant ablation in differentiated thyroid cancer patients?
    Arnoldo Piccardo
    Matteo Puntoni
    Giulia Ferrarazzo
    Luca Foppiani
    Gianluca Bottoni
    Vania Altrinetti
    Giorgio Treglia
    Mehrdad Naseri
    Bassam Dib
    Manlio Cabria
    Pierpaolo Trimboli
    Michela Massollo
    Luca Giovanella
    European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45 : 1218 - 1223
  • [33] Therapeutic efficacies of remnant ablation and radioiodine adjuvant therapy in differentiated thyroid cancer
    Liu, Yanlin
    Huang, Shuhui
    Li, Xiaohui
    Tian, Tian
    Huang, Rui
    ENDOCRINE, 2025, 87 (02) : 734 - 743
  • [34] Our first experience with low dose radioiodine ablation Therapy in low risk patients with differentiated thyroid carcinoma
    Rajkovaca, Z.
    Mijatovic, J.
    Skrobic, M.
    Mikac, G.
    Vuleta, G.
    Matavulj, A.
    Kovacevic, P.
    Ponorac, N.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2007, 34 : S356 - S356
  • [35] Clinical Outcome of Remnant Thyroid Ablation with Low Dose Radioiodine in Korean Patients with Low to Intermediate-risk Thyroid Cancer
    Ha, Seunggyun
    Oh, So Won
    Kim, Yu Kyeong
    Koo, Do Hoon
    Jung, Young Ho
    Yi, Ka Hee
    Chung, June-Key
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2015, 30 (07) : 876 - 881
  • [36] Radioiodine Remnant Ablation For Long Term Cure In Differentiated Thyroid Carcinoma - A Systematic Review And Meta-Analysis
    James, D.
    Ryan, E.
    Heath, D.
    Garry, S.
    Quinn, A.
    Boland, M.
    Young, O.
    Lowery, A.
    Kerin, M. J.
    IRISH JOURNAL OF MEDICAL SCIENCE, 2020, 189 (SUPPL 5) : S118 - S118
  • [37] Outcomes comparison of thyroxine withdrawal of 2 weeks and 3 weeks for radioiodine remnant ablation of differentiated thyroid carcinoma
    Wang, Yueqi
    Huang, Rui
    Li, Lin
    JOURNAL OF NUCLEAR MEDICINE, 2019, 60
  • [38] Decreasing the dose of radioiodine for remnant ablation does not increase structural recurrence rates in papillary thyroid carcinoma
    Kruijff, Schelto
    Aniss, Ahmed M.
    Chen, Paul
    Sidhu, Stan B.
    Delbridge, Leigh W.
    Robinson, Bruce
    Clifton-Bligh, Roderick J.
    Roach, Paul
    Gill, Anthony J.
    Learoyd, Diane
    Sywak, Mark S.
    SURGERY, 2013, 154 (06) : 1337 - 1344
  • [39] Clinical outcomes of persistent radioiodine uptake in the neck shown by diagnostic whole body scan in patients with differentiated thyroid carcinoma after initial surgery and remnant ablation
    Kim, Eui Young
    Kim, Won Gu
    Kim, Won Bae
    Kim, Tae Yong
    Ryu, Jin-Sook
    Gong, Gyungyub
    Yoon, Jong Ho
    Hong, Suck Joon
    Lee, Jeong Hyun
    Baek, Jung Hwan
    Shong, Young Kee
    CLINICAL ENDOCRINOLOGY, 2010, 73 (02) : 257 - 263
  • [40] Ablation of the thyroid remnant and 131I dose in differentiated thyroid cancer
    Doi, SAR
    Woodhouse, NJY
    CLINICAL ENDOCRINOLOGY, 2000, 52 (06) : 765 - 773